Search Results
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
progression-free survival. A trend favoring the selinexor arm was observed in the modified intent to treat (mITT) population (n=236), with a median PFS of 12.75 months in the selinexor arm compared to 7.43 months in the placebo arm (hazard ratio=0.76 [95% CI: 0.51, 1.12]; one-sided p-value=0.0791). The
More news about: Karyopharm Therapeutics Inc.
Aug 12, 2026, 17:00 ET MAYFAIR GOLD REPORTS Q2 2026 OPERATING AND FINANCIAL RESULTS
(the "PFS")1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also
More news about: Mayfair Gold Corp.
Aug 12, 2026, 16:29 ET Denison Reports Financial and Operational Results for Q2 2026, Highlighted by Significant Initial Progress from Construction Activities at the Phoenix In-Situ Recovery ('ISR') Uranium Mine
Saskatchewan. In mid-2023, the Phoenix FS was completed for the Phoenix ISR mining operation, and an update to the 2018 Pre-Feasibility Study ("2018 PFS") was completed for the Gryphon deposit as a conventional underground mining operation (the "Gryphon Update"). Based on the respective studies, both deposits
More news about: Denison Mines Corp.
Aug 12, 2026, 15:17 ET Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 12, 2026, 10:09 ET REGN DEADLINE: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline
April 29, 2026 protocol changes expanding patients eligible for PFS analysis as a key event that raised investor concerns.The May 15, 2026 announcement stated the Phase 3 trial did not reach statistical significance for its primary PFS endpoint.Why Accountability Allegations Matter
More news about: Levi & Korsinsky, LLP
Aug 12, 2026, 10:00 ET PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
improvement superior to first‑generation TRK inhibitors.In terms of long‑term therapeutic benefit, Eratrectinib exhibited favorable PFS and DOR, with a 2‑year PFS rate of 75.7% and a 2‑year DOR rate of 85.5%. These findings confirm its capacity to deliver durable disease control and sustained remission
More news about: Jiangsu Vcare Pharmatech Co., Ltd.
Aug 12, 2026, 08:17 ET Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
At the prespecified interim analysis for PFS, ivonescimab plus chemotherapy had already demonstrated a clinically meaningful and statistically significant improvement in PFS compared with tislelizumab plus chemotherapy, with a median PFS of 11.1 months versus 6.9 months (HR=0.60 [95% CI: 0.46-0.78],
More news about: Akeso, Inc.
Aug 12, 2026, 07:00 ET Defense Metals Invited by Natural Resources Canada to Submit a Full Project Proposal for its Wicheeda Processing Feasibility Program
reserve, as detailed in the Company's 2025 Pre Feasibility Study ("PFS"; refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects. The PFS shows the economic potential of the deposit and supports future
More news about: Defense Metals Corp.
Aug 12, 2026, 07:00 ET Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
DKK1.The treatment-by-DKK1 interaction was statistically significant for both PFS (p=0.0129) and OS (p=0.0027), with DKK1 modeled as a continuous variable.The BAT analysis with permutation testing reached the same conclusion (PFS p=0.018; OS p<0.001), and the data-driven cut points aligned with the
More news about: Cypherpunk Technologies Inc.
Aug 11, 2026, 20:45 ET New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
(AFFIRM-205) conducted in the aforementioned patient population. This pivotal study successfully met its primary endpoint of progression-free survival (PFS), demonstrating a highly statistically significant and clinically meaningful improvement over the control arm. LAE002 (afuresertib) also showed a favorable
More news about: Laekna
Aug 11, 2026, 10:07 ET REGN DEADLINE: The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." Following this news, the price of Regeneron's common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026,
More news about: The Gross Law Firm
Aug 11, 2026, 06:30 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 10, 2026, 12:11 ET LODE GOLD RECEIVES THREE-YEAR DRILL PERMIT AT FLAGSHIP FREMONT GOLD MINE, CALIFORNIA
program for the second half of 2026. This campaign is designed to advance the project's technical baseline in preparation for a Prefeasibility Study (PFS) to be completed in 2027.Technical Initiatives and Summer 2026 Drilling ProgramThe upcoming drilling program, slated to commence
More news about: Lode Gold Resources Inc
Aug 10, 2026, 08:14 ET Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges
More news about: Hagens Berman Sobol Shapiro LLP
Aug 10, 2026, 02:36 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
full approval for Sézary syndrome, and a registrational cohort in mycosis fungoides intended to support full approval, with progression-free survival (PFS) as the primary endpoint.About InnateInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 02:32 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
full approval for Sézary syndrome, and a registrational cohort in mycosis fungoides intended to support full approval, with progression-free survival (PFS) as the primary endpoint.About InnateInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies
More news about: Swedish Orphan Biovitrum AB
Aug 07, 2026, 02:44 ET Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
8.5 months (95% CI: 5.6~12.5 months), and the disease control rate (DCR) was 82.0%.The median progression-free survival (PFS) was 6.0 months (95% CI: 4.4~8.3 months).The median overall survival (OS) was 20.7 months (95% CI: 11.8 months ~ not estimable).In
More news about: TransThera Sciences (Nanjing) Inc.
Aug 06, 2026, 21:58 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Aug 06, 2026, 17:00 ET Wheaton Precious Metals Announces Second Quarter 2026 Results and Record Year-to-Date Production, Revenue, Earnings and Cash Flow
On July 29, 2026, Aris reported that the Prefeasibility Study ("PFS") remains on schedule for completion in H2 2026, supporting a construction decision targeted for early 2027. Project optimization work in support of the PFS includes updated mine scheduling, engineering studies and other activities
More news about: Wheaton Precious Metals Corp.
Aug 06, 2026, 13:48 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
centrally assessed ORR, per Response Assessment in Neuro-Oncology (RANO) for low grade gliomas (LGG) criteria, was 51.9%. Median PFS was not reached, and the 36-month PFS rate was 79.1%. Responses were durable, with only one patient who had previously responded experiencing subsequent disease
More news about: Nuvation Bio, Inc.
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
response rate (cORR) was 15.1%, and the disease control rate (DCR) was 61.6%. With a median follow-up of 9.9 months, the progression-free survival (PFS) reached 4.7 months. With a median follow-up of 9.4 months, overall survival (OS) data remained immature, with only 13 events (17.8%) observed.The
More news about: Innovent Biologics
Aug 05, 2026, 12:36 ET LODE GOLD COMPLETES FULL REPAYMENT OF FREMONT GOLD MINE PROPERTY SECURED LOAN AHEAD OF SCHEDULE
Plan – Late 2026Initiate Environment & Permitting work – Late 2026Complete Internal Scoping Study – Late 2026Complete PFS (Pending Upcoming Technical and Economics Evaluation) – July 2027Corporate Development & Growth: Improved
More news about: Lode Gold Resources Inc
Aug 05, 2026, 10:09 ET REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky
progression-free survival.Plaintiffs claim the public messaging understated the risk that the Phase III study would fail to show statistically significant PFS improvement.The complaint alleges the later protocol expansion and failed primary endpoint corrected prior alleged
More news about: Levi & Korsinsky, LLP
Aug 04, 2026, 12:37 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP